艾地苯醌药理作用机制及其临床研究进展  

Advances in the pharmacological mechanism of idebenone and related clinical research

作　　者：王光裕 姜维[1] 林鹏飞[1] WANG Guang-Yu;JIANG Wei;LIN Peng-Fei(Department of Neurology,Qilu Hospital of Shandong University,Jinan,Shandong 250012,China)

机构地区：[1]山东大学齐鲁医院神经内科,山东济南250012

出　　处：《国际神经病学神经外科学杂志》2022年第4期73-79,共7页Journal of International Neurology and Neurosurgery

基　　金：山东大学临床研究项目(2020SDUCRCC023)。

摘　　要：辅酶Q10是线粒体氧化呼吸链中重要的电子传递载体和抗氧化剂,而艾地苯醌是辅酶Q10的合成类似物,由日本最先研发并上市应用于临床。艾地苯醌可以发挥抗氧化、电子传递和抗炎作用,且人体对艾地苯醌有更好的吸收能力和生物利用度。截至目前针对艾地苯醌已开展了大量的临床试验,初步研究表明艾地苯醌在多种神经系统遗传性疾病及变性疾病,如Leber遗传性视神经病变、Friedreich共济失调、杜氏肌营养不良症和阿尔茨海默病中有应用的潜力。该文对艾地苯醌的药理机制及其一些重要的临床试验进行综述,为艾地苯醌进一步的临床研究和应用提供参考。Coenzyme Q10 is an important electron carrier and antioxidant for mitochondrial respiratory chain,and as a synthetic analogue of coenzyme Q10,idebenone was first developed and marketed for clinical use in Japan.Idebenone can act as an antioxidant,transfer electrons,and exert an anti-inflammatory effect,and the human body has better absorption capacity and bioavailability for idebenone.Up to now,a large number of clinical trials have been conducted for idebenone,and preliminary results show that idebenone has the potential to be used in several hereditary and degenerative diseases of the nervous system,such as Leber’s hereditary optic neuropathy,Friedreich ataxia,Duchenne muscular dystrophy,and Alzheimer’s Disease.The article reviews the pharmacological mechanism and several important clinical trials of idebenone,so as to provide a reference for further clinical research and application of idebenone.

关 键 词：艾地苯醌 辅酶Q10 LEBER遗传性视神经病变 FRIEDREICH共济失调 杜氏肌营养不良症 阿尔茨海默病 

分 类 号：R741.05[医药卫生—神经病学与精神病学]